tiprankstipranks
CytomX Therapeutics doses first patient in CX-2051 Phase 1 study
PremiumThe FlyCytomX Therapeutics doses first patient in CX-2051 Phase 1 study
24d ago
CytomX announces $5M milestone triggered in Astellas Pharma TCB collaboration
PremiumThe Fly
CytomX announces $5M milestone triggered in Astellas Pharma TCB collaboration
29d ago
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
PremiumPress Releases
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
29d ago
CytomX Therapeutics price target lowered to $3.25 from $3.30 at BMO Capital
PremiumThe FlyCytomX Therapeutics price target lowered to $3.25 from $3.30 at BMO Capital
2M ago
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
PremiumPress Releases
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
2M ago
Options Volatility and Implied Earnings Moves Today, March 11, 2024
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 11, 2024
2M ago
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
PremiumPress ReleasesCytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
3M ago
CytomX Therapeutics announces FDA clearance of IND applications for CX-2051
PremiumThe Fly
CytomX Therapeutics announces FDA clearance of IND applications for CX-2051
3M ago
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
PremiumPress Releases
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100